Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ASTRAZEN

ASTRAZEN.PH.

HealthcarePharmaceuticals & Biotechnology₹15017 cr market cap
₹6100.50 ▲ +0.94% today As of 19 Nov 2026
52-week low ₹5719.5052-week high ₹9282.00

-34.9% from the 52-week high · +5.7% above the low

AstraZeneca Pharma India Ltd. is engaged in the manufacture, distribution, and marketing of pharmaceutical products and clinical trial services. The company is headquartered in Bangalore, Karnataka and currently employs 947 full-time employees. The firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas, such as oncology, cardiovascular, renal and metabolism, and respiratory. The company also provides clinical trial services. Its cardiovascular disease and diabetic medicine brands include Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL and Xigduo XR. Its respiratory medicine brands include Symbicort and FASENRA. Its oncology medicine brands include LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex and Arimidex. The company provides services, such as self-management, diabetes diet and nutrition plans, and free telephonic counseling to patients. The company operates in over 100 countries.

The short version. Promoter holding was 75.0% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

ASTRAZEN.PH. trades 34.9% below its 52-week high and 5.7% above its 52-week low.

Change over period: —

1M+0.1%
3M-19.4%
6M-29.8%
1Y-33.1%

4 · The owners

Who holds it, and are they adding?

Promoter holding75.0%

Unchanged over 8 quarters.

Foreign institutions2.64%

Down 0.29 pts over 8 quarters.

Domestic institutions7.09%

Up 1.87 pts over 8 quarters.

Mutual fund schemes31

+2 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter75.075.075.075.075.075.075.075.00.0
FII2.932.893.032.742.712.782.682.64-0.29
DII5.224.654.565.265.565.86.087.09+1.87
Public16.8517.4617.4117.016.7316.4216.2415.27-1.58

Mutual fund holdings · Oct 2026

31 schemes hold this stock

29 the month before.

  • ICICI Prudential Quality Fund2.64% of NAV
  • Bandhan Innovation Fund2.47% of NAV
  • Baroda BNP Paribas Health and Wellness Fund2.4% of NAV
  • Baroda BNP Paribas Manufacturing Fund2.03% of NAV
  • ICICI Prudential Healthcare Fund1.99% of NAV
  • Baroda BNP Paribas Small Cap Fund1.69% of NAV
  • ICICI Prudential MNC Fund1.23% of NAV
  • Bandhan Healthcare Fund1.17% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ASTRAZEN.PH. are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ASTRAZEN.PH.

What is the ASTRAZEN.PH. share price?

ASTRAZEN.PH. (ASTRAZEN) last closed at ₹6,100.50, up 0.94% on the day. Its 52-week range is ₹5,719.50 to ₹9,282.00.

What is the market cap of ASTRAZEN.PH.?

ASTRAZEN.PH. has a market capitalisation of about ₹15,017 crore. Its price-to-earnings ratio is 85.0.

How are ASTRAZEN.PH.'s latest results?

Promoter holding was 75.0% in Sep 2026, up 0.00 points over 8 quarters.

Who owns ASTRAZEN.PH.?

As of Sep 2026, shareholding was: Promoter 75.0%, FII 2.64%, DII 7.09%, Public 15.27%.

How many mutual funds hold ASTRAZEN.PH.?

31 mutual fund schemes held ASTRAZEN.PH. in October 2026. That compares with 29 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 18 Jul 2025 · Dividend - Rs. 32
  • 05 Jul 2024 · Final Dividend - Rs. 24
  • 14 Jul 2023 · Dividend - Rs. 16
  • 07 Jul 2022 · Final Dividend - Rs. 8
  • 18 Aug 2021 · Interim Dividend - Rs. 2
  • 20 Aug 2020 · Interim Dividend - Rs. 2

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.